2010 03 01 Aqua Partners Overview

Overview presentation for Aqua Partners LLC.

1. Aqua Partners LLC
Global Specialists in the Life Science Industry
Overview
March 2010

2. AQUA PARTNERS LLC
Mission
Since 1983, our mission has been to advance life science
innovation and commercialization by leveraging Aqua’s
global network and collective experience to enhance
value creationfor our clients and their investors.

3. AQUA Partners includes a team of outstanding professionals
who contribute the specific skill sets needed to identify and
build successful partnership and investment opportunities.
Our team brings an extensive network of industry contacts
and exceptional breadth of expertise spanning:
Who We Are
M&A
Strategic partnerships
Licensing in and out
Spin-offs
Restructuring
Scientific research
Medical practice
Clinical development
Portfolio management
Venture investing

4. What We Do
We help companies access and value technology, products,
partnerships and capital worldwide.
We create, identify, support and enhance premium investment
and partnership opportunities.
We offer senior level experience in an out-sourced business
development team to develop and implement value-
enhancing strategies for clients.
We offer senior-level professional interaction, and continue to
build on long-standing relationships around the world.

5. Our Services
STRATEGIC ADVISORY
VALUATION APPRAISAL
LICENSING AND BUSINESS DEVELOPMENT
TECHNOLOGY SOURCING AND DUE DILIGENCE
MARKET RESEARCH AND OPPORTUNITY ASSESSMENT
M & A ADVISORY
SPIN-OFF AND NEW COMPANY FORMATION
RESTRUCTURING / REPOSITIONING / WORK -OUT
FUND MANAGEMENT

6. PROFESSIONAL
SERVICE
PROVIDERS
ENTREPRENEURS
GOVERNMENT
RESEARCH
INSTITUTIONS
INVESTORS
ACADEMIC
CORPORATE
REGIONAL
DEVELOPMENT
AGENCIES
INDUSTRY
MEDIA
Aqua
Partners
Deal
Flow
Leveraging Extensive Network to Access Opportunities

7. Klaus-Ulrich Berding
James E. Foley, PhD
Vivian Lee
Gerd-Albrecht Luckenbach, PhD
Gary R. Pasternack, MD, PhD
Terence Porter, PhD
Timothy Tankosic, MD
The Aqua Team

8. Klaus-Ulrich Berding
European affiliate
12yearsatDresdnerBankincorporatefinanceand
investmentresearch,focusingonlifescienceand
technology,mostrecentlyco-headforGermanyinthe
GlobalIndustryGroupofDresdnerKleinwortWasserstein.
AdvisedontoplifesciencetransactionsinEurope,including
theIPOsofSGLCarbonAG(EUR157million)andMerck
KGaA(EUR1.1billion),cross-borderM&AandlistingofFMC
AG(EUR320million)andNeuerMarktlistingofBBBiotech
(EUR124million).StudiedEconomics andBusiness
AdministrationatRuhr-UniversityBochum.

9. James E. Foley, PhD
Managing Director
Over30yearspharmaindustryexperiencespanningR&D,
business/corporatedevelopmentandlicensing.ServedasHeadof
businessdevelopmentandlicensingofpharmaceuticalsforJapan
andAsia/PacificregionsatBristolMyersSquibb,SmithKline
Beecham and GlaxoSmithKline.Extensive longstanding
relationshipswithJapanesepharmaindustry.Responsiblefor
identificationandmanagement ofmultipleworldwidein-licensing
andR&DcollaborationdealsinJapanandKoreainanti-infectives,
inflammation,respiratory,cardiovascular/metabolism,andcancer.
FormermemberBoardofDirectorsofSosei&Co.Currentlyserves
ontheBoardofSFJPharmaceuticals.Ph.D.(Physiology/
Pharmacology) from Thomas JeffersonUniversity;BA
(Biology/Chemistry)fromRutgersUniversity).HoldstheCertified
LicensingProfessional(CLP)designationfromtheLicensing
ExecutivesSociety(LES).RecipientoftheLESFrankBarnes
MentorshipAwardin2004.

10. Vivian Lee
Managing Director
Over25yearsexperienceinlifescienceadvisory,investment
andportfoliomanagement.Managed $100million
BIOMEDICINE fundasaVenturePartnerandnamedkey
personofGlobalBiomedicalPartners.Formermemberof
BoardofDirectorsofInnodia,Inc.andBoardobserverof
SyntonixPharmaceuticals.Advisedhundredsofcompanies,
investmentfirms,universitiesandgovernmentagencies
worldwide,frequentspeakeratbiotechnologyinvestment
conferencesinUS,EuropeandAsia.InvitedbytheUS
CongressionalOfficeofTechnologyAssessmenttoserveasa
reviewerforitsfirstreportoncommercialbiotechnologyin
1983.Businessanalystinthecorporateventurecapital
officeofWRGrace&Co.A.B.,BiochemistryfromHarvard
University,conductedresearchintumorimmunologyatDana
FarberCancerCenterandYaleUniversity.

11. Gerd-Albrecht Luckenbach, PhD
European Affiliate
Over20yearspharmaceuticalindustryexperiencespanning
preclinicalresearchandbusinessdevelopmentresponsibilities.
ServedinvariouscapacitiesinresearchofSandoz/Novartis
(Vienna)andBusinessDevelopment,NewTechnologiesat
Merck,KGaA(Darmstadt),wherehefocusedprimarilyon
oncologyproducts,instrumentalinthecompany’sdevelopment
oftherapeuticmonoclonalantibodyandvaccineprogram.Head
ofNewTechnologiesatEMDLexigenResearchCenter
Corporation(Boston).ConsultanttomajorEuropebasedand
Indianpharmaceuticalcompaniesinoncologyandauto-immune
diseasesaswellasout-licensingofficesofmajorGerman
universities.DiplomainBiologyandBiochemistryfrom
UniversitiesatTubingenandFreiburg.Doctoraldegreefrom
UniversityofFreiburg,Max-Planck-InstituteforImmunobioloby.
HonoraryprofessorforImmunologyatVienna,Austria.

12. Gary R. Pasternack, MD, PhD
Director
Foundednumerouslifescienceventuresandadvised
investmentfirmsandmultinationalconglomerates.
FoundedIntralytix,aBaltimore-basedleaderinapplying
bacteriophagestocontrolbacterialpathogens in
environmental,foodprocessingandmedicalsettings.
FounderofCulterra,providingautomatedsolutionsand
roboticsystemsforanatomicpathologyandhistology
analysis.FounderofChekTek,backedbySR-One,
focusingoncancerdiagnosticsandtherapeutics.Currently
servingasCEOofAquaclientAsklepionPharmaceuticals
LLC.BAinNaturalSciences,PhDinImmunologyandMD,
allfromJohnsHopkinsUniversity,whereheheldfaculty
positionsincludingDirector,DivisionofMolecular
Pathology.

13. Terence Porter, PhD
Managing Director
Over23yearsexperienceinpharmaceuticalandbiotechnology
industry;13yearsinglobalbusinessdevelopment,10yearsin
R&D.AsVicePresidentofExternalScienceandTechnologyat
GSK,heco-lednegotiationsinGSK’s$450millionacquisition
ofDomantis,thelargestGSKtechnologyM&Atransactionto
date.PreviouslyheadedGSKOncologyLicensingworldwide.
Licensingexperiencecoversprotein-basedagentsand
conventionalsmallmoleculesacrosstherapeuticareas
includingoncology,anti-infectivesandinflammation,aswellas
cuttingedgescienceandtechnologyplatforms.Coremember
ofanumberofseniormanagement committees,including
GSK’smostseniorR&Dscientificreviewandgovernance
committeefortechnologyplatformsandcompoundsupto
clinicalproof-of-concept.BSc(Hons)inBiochemistry.Ph.D.in
ChemistryfromtheUniversityofManchester,UK.

14. Timothy Tankosic, MD
Managing Director
25yearsexperienceinpharmaceutical,biotechnologyand
financialconsulting.Founded andsuccessfullysold
publishing/consulting company Drug & Market
Development.Servedasscientificadvisorfordrug
development,financialindustry,andpublishingcompanies
anddirectorofproductdevelopmentofasmalloncology
therapeuticscompany.Authorofhundredsofbusiness
reportsaddressingscientific,technological,clinical,and
marketissues.ScientificAdvisorandreviewerforScience
TranslationalMedicine(AAASpublication),AssociateEditor
ofFutureOncology,andAdvisortoFocusBankers,Inc.
A.B.fromHarvardUniversity,M.D.fromUniversityof
PittsburghSchoolofMedicine,conductedresearchatCold
SpringHarborLaboratoryforQuantitativeBiologyand
CornellUniversityMedicalCollege.

15. Strong InvestorRelationships
Principals of AQUA have long-standing relationships with the
world’s leading private equity and venture capital firms

16.  Prescient Neuroscience (Canada)
 Protez Corporation(US)
 Restoragen(US)
 Revotar Biopharmaceuticals (Germany)
 Samsung Fine Chemicals (Korea)
 Sandoz(US)
 Sanofi-Aventis (France)
 Schering-Plough(US)
 Scigen Ltd.(Singapore/Australia)
 Shionogi & Co., Ltd.(Japan)
 Simbiosys-Biowares(India/US)
 Systemix(US)
 Toyota Tsusho(Japan)
 Triage Medical(US)
 UCB Pharma (Belgium)
 Vysis(US)
 Welsh Development Agency (UK)
 Wilkerson Group (US)
 Xenova(UK)
 Zambon Group SpA (Italy)
 Zonagen(US)
 Abbott Laboratories (US)
 AdriaLaboratories(US)
 Advanced Viral Research (US)
 AmSwissPharmaceuticals (Canada)
 ArblastCo., Ltd.(Japan)
 Armstrong Pharmaceuticals (US)
 AsklepionPharmaceuticals (US)
 Bard Corporation(US)
 Bayer, AG(Germany)
 BiogenIdec(US)
 Biomet(US)
 Boehringer-Ingelheim(Germany)
 BioTechnology General(Israel/US)
 Celltech(UK)
 Cell Works (Hong Kong/US)
 CerveloPharmaceuticals (Canada)
 ChemPacific(China/US)
 CitaNeuroPharmaceuticals (Canada)
 CreatogenAG(Germany)
 Cubist Pharmaceuticals (US)
 Devax(US)
 Dynamic Bioscience (Canada)
 EffikSA(France)
Selected Clients
Principals of AQUA have advised life science industry worldwide, including
 EncysivePharmaceuticals (US)
 FerringPharmaceuticals (US)
 Genetics Institute(US)
 Goodman Co., Ltd. (Japan)
 GroupeLiphaSA(France)
 Han WhaCorporation(Korea)
 Hybridon(US)
 IkonisysUS)
 Immunomedics (US)
 InotebSA(France)
 Intergen(US)
 Israel Chemicals Ltd.(Israel)
 Janssen/ J&J(US)
 MedaforSA(France)
 Medmira, Inc(Canada)
 Merck KGaA(Germany)
 Molecular Oncology (US)
 Myogen(US)
 Nanosystems (US)
 OmniviralTherapeutics(US)
 OrtecInternational(US)
 PharmingBV(Netherlands)
 Polymer Technology Systems (US)

17. Accessing Emerging Product Opportunities
Principals of AQUA have managed a portfolio of venture investments including companies
developing the world‘s most promising new therapeutic technologies and products.

18. Industry Depth
Expertise across broad range of therapeutic categories, including
Anti-infectives
Oncology
Cardiovascular
CNS
Diabetes/Metabolic
Women’s health
Drug Delivery

19. Anti-infectives
Selected Assignments / Investments
Assessment and due diligence in support of first venture capital investment in Liposome
Technology Inc. (later Alza/J&J)
In-licensing novel hospital-based antibiotic compounds from Asia/Pacific Rim to US
venture-backed anti-infectives company
Strategy for novel antiviral therapeutic platform based on viral entry inhibition
Valuation assessment and positioning for branded generic recombinant Hepatitis B vaccine
Opportunity assessment and due diligence for potential investment by Asian conglomerate
in US HIV therapeutic company
Investor in
•Anadys (antivirals and Bacterial Translation Inhibitors for drug-resistant pathogens)
•Enanta (macrolide antibiotics)

20. Oncology
Selected Assignments / Investments
Strategy for accessing emerging biotechnology products for Adriain anticipation of
doxorubicin patent expiration
Restructuring investment in liver cancer targeted therapy
Financial and strategic advice in positioning robotic digital microscopy platform for cancer
diagnosis and management
Accessing global licensing opportunities in tyrosine kinasereceptor targets
Editorial leadership of Future Oncology publication
Investor in
•TransMolecularInc. (brain cancer therapeutics)
•Cytokinetics(small molecule oncology therapeutics)
•Sunesis(small molecule oncology therapeutics)
•Exelixis(genomics-based oncology drug development)

21. Cardiovascular
Selected Assignments / Investments
Strategy for European market positioning of drug treating acute
decompensated heart failure
Advised on acquisition of private US vascular stent company
Advised on acquisition of private US cardiovascular imaging company
Restructuring advice on sale of clinical stage GLP-1 drug for treatment of
congestive heart failure
Investor in
•Devax (bifurcated stent)
•Lexigen Pharmaceuticals (small molecule hypertension drugs)
•Cytokinetics (small molecule activator of cardiac myosin)

22. CNS
Selected Assignments / Investments
Partnering strategy for preclinical stage neuroprotective compounds
Strategy for developing small molecule compounds for neuropathic and
inflammatory pain
Positioning small molecule drugs in development for treatment of Parkinson’s
disease
Investor in
•Renovis (stroke neuroprotection)
•Memory Pharmaceuticals (cognitive impairment)
•Micrus (cerebral aneurysms)
•Adolor (pain management)

23. Other Selected Assignments / Investments
Diabetes/Metabolic
Accessing innovative products for treatment of diabetes and related complications
Investor in Innodia (obesity and Type 2 diabetes)
Investor in Arena Pharmaceuticals (obesity)
Women’s health
Advised on launch of recombinant human gonadotropin products for infertility treatment
Drug Delivery
Commercialization and partnering for several liposomal formulation technologies
Nanoparticle delivery of inhaled steroids
Metered dose inhaler formulation markets
Investor in Syntonix (pulmonary delivery of protein drugs)
Divestiture of sustained release delivery polymer system for treatment of periodontal
disease

24. Global Arbitrage
Emphasizing cross-border opportunities to build global presence
Ortec International
•Equity investment by European venture firm in US tissue engineering company
ChemPacific
•Outsourcing strategy for chemistry/API manufacture in China
Micrus
•Migration from US to Switzerland to access EU markets, later facilitating US IPO
BioTechnology General
•Migration of corporate presence from Israel to US to access venture financing and IPO
Innodia
•Migration from France to Canada facilitating venture financing
Scigen
•Migration from US to Singapore to public offering in Australia
Revotar Biopharmaceuticals
•Spin-off from US public biotechnology company (Encysive Pharmaceuticals) migrated
to Germany to facilitate 3X non-dilutive financing

25. Contact us: AQUA PARTNERS LLC
PO Box 1247
Los Altos, CA 94022
Telephone: [phone]
Fax: [phone]
James Foley, PhD
[email protected]
Vivian Lee
[email protected]
Terence Porter, PhD
[email protected]
Timothy Tankosic, MD
[email protected]